T Cell News and Research

Latest T Cell News and Research

CD4 Initiative selects Zyomyx's CD4 POC technology as best for measuring CD4 T-cell count in HIV/AIDS patients

Zyomyx, Inc., a leader in chip-based bioanalysis technologies, today announced that its readerless CD4 point-of-care (POC) technology was selected by Imperial College London's CD4 Initiative as the best-performing POC test method for measuring CD4 T-cell count in HIV/AIDS patients. Zyomyx's CD4 assay is now the only remaining POC product being supported by the CD4 Initiative.

17 Nov 2009

New Web-based application for tracking the H1N1 flu virus across the globe

New methods of studying avian influenza strains and visually mapping their movement around the world will help scientists more quickly learn the behavior of the pandemic H1N1 flu virus, Ohio State University researchers say.

17 Nov 2009

Titanium dioxide nanoparticles causes systemic genetic damage in mice, say researchers

Titanium dioxide (TiO2) nanoparticles, found in everything from cosmetics to sunscreen to paint to vitamins, caused systemic genetic damage in mice, according to a comprehensive study conducted by researchers at UCLA's Jonsson Comprehensive Cancer Center.

17 Nov 2009

Targeting normal cells that surround cancer cells increases the effectiveness of traditional anti-cancer treatments

Targeting the normal cells that surround cancer cells within and around a tumor is a strategy that could greatly increase the effectiveness of traditional anti-cancer treatments, say researchers at The Wistar Institute.

17 Nov 2009

Antioxidant found in vegetables can protect cells from damage caused by infection and injury

Scientists at the University of Pennsylvania School of Medicine discovered that a dietary antioxidant found in such vegetables as broccoli and cauliflower protects cells from damage caused by chemicals generated during the body's inflammatory response to infection and injury. The finding has implications for such inflammation-based disorders as cystic fibrosis (CF), diabetes, heart disease, and neurodegeneration.

17 Nov 2009

HDAC inhibitors: New therapy for treating breast cancer

A powerful new breast cancer treatment could result from packaging one of the newer drugs that inhibits cancer's hallmark wild growth with another that blocks a primordial survival technique in which the cancer cell eats part of itself, researchers say.

17 Nov 2009

Healthy adults may have better immunity to 2009 H1N1 influenza virus, says study

A new study shows that molecular similarities exist between the 2009 H1N1 influenza virus and other strains of seasonal H1N1 virus that have been circulating in the population since 1988. These results suggest that healthy adults may have a level of protective immune memory that can blunt the severity of infection caused by the 2009 H1N1 influenza virus.

17 Nov 2009

Researchers attempt to slow the pace of infectious organisms' evolution to keep today's drugs effective

Infectious organisms that become resistant to antibiotics are a serious threat to human society. They are also a natural part of evolution. In a new project, researchers at the University of Gothenburg are attempting to find substances that can slow the pace of evolution, in order to ensure that the drugs of today remain effective into the future.

17 Nov 2009

Mount Sinai School of Medicine to participate in Phase 2 clinical trial to test gene therapy treatment for Alzheimer's disease

Mount Sinai School of Medicine is one of 12 sites nationwide participating in the first Phase 2 clinical trial to test gene therapy treatment for Alzheimer's disease. The study is the first multicenter neurosurgical intervention in Alzheimer's research in the U.S.

17 Nov 2009

Using cell phones while crossing streets can be dangerous for older pedestrians

Two new studies of pedestrian safety found that using a cell phone while hoofing it can endanger one's health. Older pedestrians, in particular, are impaired when crossing a busy (simulated) street while speaking on a mobile phone, the researchers found.

16 Nov 2009

Stem cell therapy to treat heart, lung and vascular diseases show positive results

A Florida cardiologist is using stem cell therapy to treat patients who suffer from a range of heart, lung and vascular illnesses. The results have been extraordinary.

16 Nov 2009

BrainStorm Cell's therapeutic approach has potential for treatment of neurodegenerative diseases

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeutics, is pleased to announce that the company’s therapeutic approach for treating neurodegenerative diseases, particularly ALS and Parkinson’s disease, was found to have a positive effect in a mouse model of multiple sclerosis (MS).

16 Nov 2009

Semafore Pharmaceuticals to present SF1126 Phase I data at the 51st ASH meeting

Researchers are scheduled to present Phase I data relating to Semafore Pharmaceuticals’ lead product candidate, SF1126, as a treatment for patients with relapsed and refractory myeloma during the 51st American Society of Hematology (ASH) Annual Meeting, December 5 - 8, 2009, at the Ernst N. Morial Convention Center in New Orleans, LA.

16 Nov 2009

Seattle Genetics commences phase I clinical trial of SGN-75 ADC for metastatic renal cell carcinoma

Seattle Genetics, Inc. today announced that it has initiated a phase I clinical trial of SGN-75 for metastatic renal cell carcinoma and relapsed and refractory non-Hodgkin lymphoma. SGN-75 is an antibody-drug conjugate (ADC) targeting CD70 that utilizes the company’s proprietary technology.

16 Nov 2009

Interim data from Hollis-Eden Pharmaceuticals' Apoptone Phase I/II clinical trial presented

Hollis-Eden Pharmaceuticals, Inc., today reported preliminary results of its ongoing Phase I/II clinical trial with Apoptone® (HE3235) for hormone-resistant prostate cancer (also called castrate-resistant prostate cancer or CRPC). Presented at the Molecular Targets and Cancer Therapeutics Conference, which is co-sponsored by the AACR, NCI and EORTC, the poster is titled: "Results of preclinical and clinical Phase I/II open-label dose-ranging trial with HE3235, a synthetic adrenal hormone, in Castrate Resistant Prostate Cancer (CRPC)."

16 Nov 2009

Cord Blood reports its 10Q filing with the U.S. SEC for the three and nine-month period ended September 30, 2009

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, announced today that its 10Q filing with the U.S. SEC for the three and nine-month period ended September 30, 2009, confirmed its announcements throughout 2009 that it is significantly reducing debt.

16 Nov 2009

Gentium to present Defibrotide trial data at the ASH meeting

Gentium S.p.A. announced today that results from the Company’s Phase II/III Pediatric Prevention trial and Phase III Treatment trial for Defibrotide of Hepatic Veno-Occlusive Disease will be presented at American Society of Hematology Conference (ASH), December 5-8 in New Orleans.

16 Nov 2009

Erbitux recognized as one of the major clinical cancer advances of 2009

The American Society of Clinical Oncology (ASCO) has once again recognized Erbitux® (cetuximab) as one of the major clinical cancer advances of 2009. This year Erbitux was selected by ASCO for providing the first significant increase in survival for 30 years in the treatment of patients with 1st-line recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).

16 Nov 2009

Fate Therapeutics announces the completion of $30 million Series B financing

Fate Therapeutics, Inc. announced today that it has completed a $30 million Series B financing led by OVP Venture Partners. Joining OVP Venture Partners in the financing is a syndicate of corporate investors, including Astellas Venture Management, Genzyme Ventures and a third undisclosed corporate investor.

16 Nov 2009

Advanced Cell Technology to raise funds through private placements

Advanced Cell Technology, Inc., announced today that it has entered into definitive agreements on three private placements with institutional and other accredited investors under which the Company has received definitive commitments in excess of $15 million.

16 Nov 2009

T Cell News and Research

Latest T Cell News and Research

CD4 Initiative selects Zyomyx's CD4 POC technology as best for measuring CD4 T-cell count in HIV/AIDS patients

New Web-based application for tracking the H1N1 flu virus across the globe

Titanium dioxide nanoparticles causes systemic genetic damage in mice, say researchers

Targeting normal cells that surround cancer cells increases the effectiveness of traditional anti-cancer treatments

Antioxidant found in vegetables can protect cells from damage caused by infection and injury

HDAC inhibitors: New therapy for treating breast cancer

Healthy adults may have better immunity to 2009 H1N1 influenza virus, says study

Researchers attempt to slow the pace of infectious organisms' evolution to keep today's drugs effective

Mount Sinai School of Medicine to participate in Phase 2 clinical trial to test gene therapy treatment for Alzheimer's disease

Using cell phones while crossing streets can be dangerous for older pedestrians

Stem cell therapy to treat heart, lung and vascular diseases show positive results

BrainStorm Cell's therapeutic approach has potential for treatment of neurodegenerative diseases

Semafore Pharmaceuticals to present SF1126 Phase I data at the 51st ASH meeting

Seattle Genetics commences phase I clinical trial of SGN-75 ADC for metastatic renal cell carcinoma

Interim data from Hollis-Eden Pharmaceuticals' Apoptone Phase I/II clinical trial presented

Cord Blood reports its 10Q filing with the U.S. SEC for the three and nine-month period ended September 30, 2009

Gentium to present Defibrotide trial data at the ASH meeting

Erbitux recognized as one of the major clinical cancer advances of 2009

Fate Therapeutics announces the completion of $30 million Series B financing

Advanced Cell Technology to raise funds through private placements

Immunology eBook

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Newsletters you may be interested in